In the shadow of COVID-19, experts at the BIO Asia-Taiwan conference on Wednesday warned of present and future challenges for the biotech industry. Changes in manufacturing logistics and financial distress will continue to cause concern for the industry.
HONG KONG – Mumbai, India-headquartered Glenmark Pharmaceuticals Ltd. have released statistically significant top-line results from a phase III trial showing that Fabiflu (favipiravir), an antiviral pyrazine RNA polymerase inhibitor, can treat cases of mild to moderate COVID-19 in four days.
Chinese biotech startup Lynk Pharmaceuticals Co. Ltd., of Hangzhou, has in-licensed global rights from Kobe University and Riken Research Institute in Japan to develop renin-angiotensin system (RAS) inhibitors, which have a novel mechanism of action that can increase chances of developing anti-RAS cancer drugs.
A medical device company has partnered with a couple of investment firms to tap new technologies and help bring them back to China. Venus Medtech (Hangzhou) Inc. formed a health care investment platform, Ascendum Capital Partners, to invest in new medical devices and technologies around the world, particularly in the cardiovascular and lung disease spaces.
HONG KONG – Chugai Pharmaceutical Co. Ltd. is hoping to start phase I trials for an as-yet-unnamed digital solution for measuring pain levels in endometriosis patients that it is co-developing with Biofourmis Inc.
HONG KONG – Tokyo-based Daiichi Sankyo Co. Ltd. has hit its goals in a phase III study testing the use of prasugrel hydrochloride in thrombotic stroke patients.
With no new cases reported for more than 100 days, Taiwan appears to have successfully contained the spread of COVID-19 and has drawn attention to its medical achievements. Experts said at BIO Asia-Taiwan conference this week that with continuous government and investor support, the East Asian nation could move further up to join other leading biotech players.
HONG KONG – Daejeon, South Korea-based biotechnology company G2GBIO Inc. has raised ₩11.4 billion (US$9.53 million) from a series B financing round, with the funds to be used on clinical trials for a sustained-release Alzheimer’s treatment as well as nonclinical trials for diabetes and sustained-release postoperative pain treatments.
HONG KONG – Seoul-based Vuno Inc. faces the happy dilemma of being able to choose from multiple partnership offers to add to the string of recent deals inked by the South Korean company. The company’s most recent deal is an agreement with Dong Wha Pharmaceutical Co. Ltd. for a ₩3 billion ($2.5 million) investment. For Dong Wha, the deal is a culmination of a three-year effort to diversify its business via active investments in the latest health care trends.
In the shadow of COVID-19, experts at the BIO Asia-Taiwan conference on Wednesday warned of present and future challenges for the biotech industry. Changes in manufacturing logistics and financial distress will continue to cause concern for the industry.
RSS
